Copiktra is owned by Secura.
Copiktra contains Duvelisib.
Copiktra has a total of 5 drug patents out of which 0 drug patents have expired.
Copiktra was authorised for market use on 24 September, 2018.
Copiktra is available in capsule;oral dosage forms.
Copiktra can be used as for the treatment of patients with follicular lymphoma (fl); for the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll).
Drug patent challenges can be filed against Copiktra from September, 2022.
The generics of Copiktra are possible to be released after 17 May, 2032.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8193182 | SECURA | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
Feb, 2030
(7 years from now) | |
USRE46621 | SECURA | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
May, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9216982 | SECURA | Certain chemical entities, compositions and methods |
Jan, 2029
(5 years from now) | |
US9840505 | SECURA | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
Jan, 2032
(8 years from now) | |
US11312718 | SECURA | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
Jan, 2032
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 24, 2023 |
Orphan Drug Exclusivity (ODE) | Sep 24, 2025 |
Drugs and Companies using DUVELISIB ingredient
NCE-1 date: September, 2022
Market Authorisation Date: 24 September, 2018
Treatment: For the treatment of patients with follicular lymphoma (fl); For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)
Dosage: CAPSULE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic